Optain Health has closed a $26 million Series A funding round to accelerate the deployment of its AI-powered retinal screening technology across the United States. The round was led by Insight Partners with participation from existing investors and strategic investments from seven prominent health systems, including Memorial Hermann Health System, Northwell Health, Novant Health, The Ohio State University Wexner Medical Center, and UPMC.
The company's platform leverages Oculomics, an emerging field that uses retinal imaging to detect both ocular and systemic diseases. Optain's portable robotic camera captures high-quality retinal images without requiring pupil dilation, streamlining the screening process for patients and providers. The system's AI workflows analyze these images to identify sight-threatening conditions, including diabetic retinopathy, glaucoma, and age-related macular degeneration, while also assessing cardiovascular disease risk markers visible in retinal vasculature.
"Our mission is simple: faster, easier, more equitable disease screening," said Jeff Dunkel, CEO, Optain. "After two years of major international growth, we are ready to scale in the U.S. This Series A funds our enterprise deployments, opens new markets, and pushes the frontier of what the retina can reveal."
The strategic partnerships with health systems represent a significant expansion opportunity for Optain. These seven systems collectively serve 28 million patients across 25 states and will begin implementing the platform to enhance screening accessibility and improve patient outcomes. The deployment strategy focuses on closing care gaps in underserved populations where access to specialized eye care remains limited.
The technology foundation stems from more than a decade of research conducted by Professor Mingguang He in Australia. As part of its growth strategy, Optain plans to maintain strong ties to its Australian roots by making substantial investments in local R&D operations and expanding its Australian team to spearhead global expansion efforts outside the United States.
"We're proud to be translating world-class Australian science into real-world impact," said Dr. Zachary Tan, President of Optain. "Exporting Australian AI innovation to improve equitable access to healthcare and patient outcomes around the world is a mission we are proud to lead."
The funding will enable Optain to scale its enterprise deployments, enter new geographic markets, and advance research into additional applications of retinal imaging for whole-body health assessment. This investment positions the company to address the growing demand for accessible, efficient screening solutions that can detect multiple conditions through a single, non-invasive examination.
Click here for the original news story.